Clinical evaluation of a new high efficiency hemodialyzer: polysynthane.
Two increasingly common characteristics of the American chronic hemodialysis (HD) population, high hematocrit and large body size, may render the currently recommended adequacy targets difficult to achieve, even with very efficient dialyzers. In a group of patients with these characteristics, we assessed the ability of a new high efficiency dialyzer (PSN210; Baxter Healthcare Corporation) to achieve the currently recommended adequacy targets. Six patients (mean pre-HD weight and hematocrit, 90.3 +/- 18.0 kg and 0.40 +/- 0.03 kg, respectively) were evaluated. At prescribed blood and dialysate flow rates of 400 and 800 ml/min, respectively, and a mean treatment duration of 4 hrs, mean delivered urea Kt/V and reduction ratio (URR) were 1.38 +/- 0.25 and 0.73 +/- 0.07, respectively. For the same flow rates, whole blood clearances for urea, creatinine, and phosphate were 315 +/- 13, 246 +/- 28, and 260 +/- 27 ml/min, respectively. These data indicate this dialyzer has an efficient mass transfer design allowing adequate dialysis to be delivered even to very large patients under high efficiency conditions.
Clark
W R
WR
Renal Division, Baxter Healthcare Corporation, McGaw Park, Illinois, USA.
Shinaberger
J H
JH
D000328:Adult; D000368:Aged; D001672:Biocompatible Materials; D001824:Body Constitution; D015314:Dialysis Solutions; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D010316:Particle Size; D011108:Polymers; D006435:Renal Dialysis / Q000295:instrumentation*; D012995:Solubility
D001672:Biocompatible Materials; D015314:Dialysis Solutions; D008567:Membranes, Artificial; D011108:Polymers